Pretargeted α Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N‴-Tetraacetic Acid-Biotin

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 3137-3146

  Yao, Zhengsheng ^a   Zhang, Meili ^a   Garmestani, Kayhan ^a   Axworthy, Donald B ^d   Mallett, Robert W ^d   Fritzberg, Alan R ^d   Theodore, Lou J ^d   Plascjak, Paul S ^a,b   Eckelman, William C ^a,b   Waldmann, Thomas A ^a   Pastan, Ira ^a   Paik, Chang H ^a   Brechbiel, Martin W ^c   Carrasquillo, Jorge A ^a,e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Poniard Pharmaceuticals Inc   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID BIOTIN BISMUTH 213; BIOTIN DERIVATIVE; BIOTINIDASE; BISMUTH 213; GALACTOSE; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; STREPTAVIDIN; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER INHIBITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; BIOTIN; BISMUTH; BONE MARROW; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; KIDNEY; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; SPLEEN; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2442474076     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0171     Document Type: Article

References (50)

1. Carrasquillo JA. Radioimmunotherapy of leukemia and lymphoma. In: Wagner H, editor. Principles of nuclear medicine. 2nd Edition. W. B. Saunders and Co.; 1996. p. 1117-32.
2. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer (Phila) 1997;80:2706-11.
3. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14: 1974-81.
4. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 1995;86:4063-75.
5. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a Phase III prospectively randomized controlled trial of Zevalin (TM) radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol-Hematol 2001;39:181-94.
6. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17: 3793-803.
7. Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol 2000;10:73-93.
8. Larson SM. Clinical radioimmunodetection, 1978-1988: overview and suggestions for standardization of clinical trials. Cancer Res 1990; 50:892s-8s.
9. Yu B, Carrasquillo J, Milenic D, et al. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J Clin Oncol 1996;14:1798-809.
10. Mulligan T, Carrasquillo JA, Chung Y, et al. Phase I study of intravenous Lu-177-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1995;1: 1447-54.
11. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998;16:3270-8.
12. Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and dosimetry of an α-particle emitter labeled antibody: Bi-213-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999;40:1935-46.
13. McDevitt MR, Finn RD, Ma D, Larson SM, Scheinberg DA. Preparation of α-emitting Bi-213-labeled antibody constructs for clinical use. J Nucl Med 1999;40:1722-7.
14. Zalutsky MR, Akabani G, Cokgor I, et al. Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection cavity patients. Eur J Nucl Med 1999;26:1215.
15. Kennel SJ, Mirzadeh S. Vascular targeted radioimmunotherapy with Bi-213: an α-particle emitter. Nucl Med Biol 1998;25:241-6.
16. Zhang ML, Yao ZS, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213. Blood 2002;100:208-16.
17. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-8.
18. Jain RK. Barriers to drug-delivery in solid tumors. Sci Am 1994; 271:58-65.
19. Saga T, Neumann RD, Heya T, et al. Targeting cancer micrometastases with monoclonal-antibodies: a binding-site barrier. Proc Natl Acad Sci USA 1995;92:8999-9003.
20. Goodwin DA. New methods for localizing infection: a role for avidin-biotin? [editorial; comment]. J Nucl Med 1992;33:1816-8.
21. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51:5960-6.
22. Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA X anti-DTPA-indium bispecific antibody. J Nucl Med 1998; 39:1172-8.
23. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU- 10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000;6:406-14.
24. Breitz HB, Weiden PL, Beaumier PL, et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and Y-90-DOTA-biotin. J Nucl Med 2000;41:131-40.
25. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 2000;97:1802-7.
26. Schultz J, Lin Y, Sanderson J, et al. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res 2000;60:6663-9.
27. Camera L, Kinuya S, Garmestani K, et al. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur J Nucl Med 1994;21:640-6.
28. Pai LH, Carrasquillo JA, Gansow O, et al. Imaging and Phase I study of 111In and 90Y labeled anti-Lewis Y monoclonal antibody. Clin Can Res 1999.
29. Yao ZS, Zhang ML, Axworthy DB, et al. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and Y-90-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N′,N‴-tetraacetic acid (DOTA)-biotin. Cancer Res 2002;62:5755-60.
30. Pastan I, Lovelace ET, Gallo MG, et al. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res 1991;51:3781-7.
31. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 1981;126:1393-7.
32. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989;86:10029-33.
33. Theodore LJ, Axworthy DB. Cluster clearing agents. PCT Application International, Publication Number WO 97/46098, June 1997. WIPO, Geneva, Switzerland.
34. Axworthy DB, Theodore LJ, Gustavson LM, Reno JM. Biotinidase-resistant-biotin conjugates. United States patent US Feb 21, 1995;5608060.
35. Kobayashi H, Wu CC, Yoo TM, et al. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J Nucl Med 1998;39:829-36.
36. Lagunas-Solar MC, Carvacho OF, Nagahara L, Mishra A, Parks NJ. Cyclotron production of no-carrier-added 206Bi (6.24 d) and 205Bi (15.31 d) as tracers for biological studies and for the development of a -emitting radiotherapeutic agents. Int J Rad Appl Instrum Part A 1987; 38:129-37.
37. Garmestani K, Yao Z, Zhang M, et al. Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides. Nucl Med Biol 2001;28:409-18.
38. Wu CC, Brechbiel MW, Gansow OA. An improved generator for the production of Bi-213 from Ac-225. Radiochimica Acta 1997;79: 141-4.
39. Loevinger R, Berman M. Calculating the absorbed dose from biologically distributed radionuclides. New York: The Society of Nuclear Medicine; 1976.
40. Howell RW, Azure MT, Narra VR, Rao DV. Relative biological effectiveness of α-particle emitters in-vivo at low-doses. Radiat Res 1994;137:352-60.
41. Li Y, Rizvi SMA, Ranson M, Allen BJ. Bi-213-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. Br J Cancer 2002;86:1197-203.
42. Hartmann F, Horak EM, Garmestani K, et al. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor α-expressing lymphoma utilizing the α-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res 1994;54:4362-70.
43. Zhang ML, Zhang Z, Garmestani K, et al. Multistep targeting of ALCL tumor bearing mice with a tetra-valent single-chain antibody-streptavidin fusion protein. Blood 2001;98:2479.
44. Stevens G, Joiner M, Joiner B, Johns H, Denekamp J. Early detection of damage following bilateral renal irradiation in the mouse. Radiother Oncol 1991;20:124-31.
45. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer (Phila) 1997;80:2591-610.
46. Behr TM, Behe M, Stabin MG, et al. High-linear energy transfer (LET) α versus low-LET β emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of Bi-213- versus Y-90-labeled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res 1999;59:2635-43.
47. Kennel SJ, Mirzadeh S, Eckelman WC, et al. Vascular-targeted radioimmunotherapy with the α-particle emitter At-211. Radiat Res 2002;157:633-41.
48. Kennel SJ, Boll R, Stabin M, Schuller HM, Mirzadeh S. Radioimmunotherapy of micrometastases in lung with vascular targeted Bi-213. Br J Cancer 1999;80:175-84.
49. Davis IA, Glowienka KA, Boll RA, et al. Comparison of (225) actinium chelates: tissue distribution and radiotoxicity. Nucl Med Biol 1999;26:581-9.
50. Kennel SJ, Chappell LL, Dadachova K, et al. Evaluation of Ac-225 for vascular targeted radioimmunotherapy of lung tumors. Cancer Biother Radiopharm 2000;15:235-44.